Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's Why This Growth Stock Is Already My 2022 Winner

TheMotleyFool

0 0

Here's Why This Growth Stock Is Already My 2022 Winner: https://g.foolcdn.com/editorial/images/708138/nurse-is-listening-with-a-stethoscope-a-patients-chest.jpg

As Thanksgiving approaches, 2022 is coming to a close -- and what a year the stock market had. The S&P 500 is still down 21% year to date. Most growth stocks have taken a beating this year. But amid this downfall, some companies still shone, giving investors a glimpse of hope.

One such company is oncology drugmaker Exelixis (NASDAQ: EXEL). Its star product has captured everyone's attention. But the company has more in store to drive growth in the coming years. Here are some reasons why this growth stock is my winner this year.

Source Fool.com

Like: 0

EXEL

Share